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Miscellaneous Disorders of Calcium and Bone Metabohsm
Gregory R. Mundy, MD*

Pathophysiology of Hypercalcemia

D

uring this section of the meeting a miscellaneous group of
disorders affecting calcium homeostasis and bone metabolism were reviewed by investigators with special experience
with these particular disorders. Kanis et al (1) discussed the distribution of calcium in normal plasma, the importance of binding to plasma proteins, and the effects that this has on interpretation of measurements of total plasma calcium. They discussed
the transport of calcium between the extracellular fluid and the
gut, bone, and the kidney and stressed the importance of the
kidney and in particular renal tubular calcium reabsorption
in calcium homeostasis. They then reviewed how careful determination of urine calcium excretion may give insight into
calciumfluxesfrom the skeleton and calcium absorption from
the gut.

Hypercalcemia: Solid Thmors
One of the commonest causes of hypercalcemia is malignant
disease. Kanis et al (1) indicated that hypercalcemia occurs in
malignant disease in a number of different settings. Martin (2)
discussed a newly described factor associated with one of these
settings, namely the humoral hypercalcemia of malignancy. In
this syndrome, a solid tumor produces a humoral factor which
alone or in concert with other factors stimulates osteoclastic
bone resorption, enhances renal tubular calcium reabsorption,
and increases urinary cyclic AMP. Martin described a biological
activity from one of these tumors which stimulated adenylate
cyclase activity in bone cells and in renal membranes, whose
effects were blocked by synthetic antagonists to parathyroid hormone (PTH) and which was not affected by antisera to PTH. He
described the purification and molecular cloning of this factor
and the biological effects of synthetic fragments. This factor,
which was referred to as the PTH-related protein, has considerable homology to authentic parathyroid hormone in the N-terminal region since eight of the first 13 amino acids are identical. It
binds to the PTH receptor and activates it. It stimulates bone resorption and renal tubular calcium reabsorption and increases
plasma calcium in vivo. Immunoreactive PTH-rP was found in a
variety of tumors, some of which are associated with hypercalcemia and some of which are not.

Mechanisms of Hypercalcemia in
Hematologic Malignancies
Factors which are implicated in the hypercalcemia associated
with hematologic malignancies were described (3). In my-
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eloma, hypercalcemia occurs as a consequence of increased
bone resorption usually associated with decreased glomemlar
filtration. In this malignancy, the tumor cells produce a cytokine
(lymphotoxin) which stimulates osteoclastic bone resorption in
vitro and in vivo and increases plasma calcium in vivo. In some
lymphomas associated with hypercalcemia, there is increased
production of 1,25-dihydroxyvitamin D. This has been found in
association with adult T-cell lymphomas, with B-cell lymphomas, and in occasional cases with Hodgkin disease. It seems
likely in these circumstances that the neoplastic lymphoid cells
have developed the capacity to synthesize 1,25-dihydroxyvitamin D.

Paget Disease of Bone: Assessment, Therapy, and
Secondary Prevention
Bijvoet et al (4) gave an update of Paget disease of bone. This
bone disorder is characterized by a primary abnormality in the
osteoclast which is accompanied by morphologic abnormalities
which include increased multinucleation, increased functional
capacity, and the presence of intranuclear inclusion bodies.
These intranuclear inclusion bodies seem likely to be due to a
slow vims which is probably the primary cause of this disorder.
Paget disease which is associated with pain or deformity can be
treated with calcitonin or with one of the dmgs of the bipbosphonate family. Bijvoet et al stressed the utility of the newer biphosphonates, particularly the amino biphosphonates, which
are more potent than thefirst-generationagents, produce fewer
side effects, and may lead to better and more prolonged
therapeutic responses.

Renal Calculi: Update
Pak (5) discussed the current status of pathophysiology, diagnosis, and medical management of renal calculi. He reviewed
the history of the pathophysiologic approach to diagnosis and
treatment of recurrent renal calculi. He discussed the three
major mechanisms thought responsible for hypercalciuria—
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absorptive hypercalciuria, resorptive hypercalciuria, and renal
leak hypercalciuria—and reported on other less common mechanisms including the primary renal phosphate leak group, the
group associated with primary enhancement of 1,25 D production, and the group with combined renal tubular disturbances
which lead to hypercalciuria. Pak reviewed the role of hypocitmria which is present in 70% to 80% of patients with recurrent renal calculi and hypercalciuria. Hypocitmria has multiple
causes, is easily diagnosed, and readily corrected by potassium
citrate, an effective dmg which reduces stone formation in these
patients. In discussing the utility of medical prevention of recurrent renal calculi with the use of thiazides and potassium citrate,
he suggested that despite the recent striking advances in the surgical approach to recurrent renal stones, medical therapy had a
useful place in prevention of further development of stones, reduction of the need for further surgery, and as a cost-effective
form of therapy. However, he stressed that medical therapy does
not cure the underlying defect responsible for this disorder
which still requires diagnostic evaluation for careful choice
of therapy.

Current Problems in Renal Osteodystrophy
Recent concepts of the pathophysiology of renal bone disease
were discussed by Boyce et al (6). Renal bone disease is comprised of three main pathologic entities: osteitisfibrosa(secondary hyperparathyroidism), osteomalacia responsive to vitamin
D metabolites, and aluminum bone disease. Boyce et al showed
that aluminum is an important pathophysiologic agent in bone
disease associated with chronic renal disease and is responsible
for a syndrome characterized by resistance to therapy with 1,25dihydroxyvitamin D, a relative decrease in semm immunoreactive parathyroid hormone, a relative decrease in alkaline phosphatase, and the bone biopsy picture of osteomalacia. There are
several variants to the bone biopsy picture. These include pure
osteomalacia with low mineralization rates, thick osteoid seams
and no evidence of osteitis fibrosa, a mixed picture of osteomalacia and osteitisfibrosa,and an aplastic or adynamic biopsy
appearance associated with low bone tumover. They pointed out
that patients who are particularly atriskfor aluminum intoxication were those who were hyperabsorbers of aluminum, those
who used dialysis water in which aluminum was not removed by
treatment of water with reverse osmosis or deionization, and
those who ingest large amounts of aluminum binders. They then
reviewed the difficulties in diagnosis of aluminum bone disease
without a bone biopsy. This can be made with the desferrioxamine test followed by measurement of the semm aluminum response, although this test is not uniformly reliable. They indicated the potential problems of patients with aluminum bone
disease who were subjected to parathyroidectomy and concluded by indicating that hypercalcemia in a patient with chronic
renal disease should not be treated by parathyroidectomy unless
aluminum bone disease has been carefully excluded, that aluminum toxicity is still an important cause of renal bone disease,
and that the role of parathyroidectomy in exacerbating aluminum bone disease in a patient with underlying increased aluminum content in bone remains unclear.
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The Pathogenesis and Clinical Course of Multiple
Endocrine Neoplasia l^pe 2A
The session concluded with a review of the multiple endocrine neoplasia type 2A (MEN-2A) syndrome by Gagel (7).
This syndrome comprises medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia. It was first described by Sipple in 1961. Gagel showed how this syndrome has
gone through three phases beginning with the clinical description in the 1960s, followed by the use of calcitonin measurement
in the diagnosis and screening of asymptomatic patients in the
1970s, and then by recent advances in understanding the abnormalities in gene function which lead to the molecular derangements in patients with this syndrome. He pointed out that the
thyroid disease almost always occurs first and that the adrenal
disease is a particularly difficult problem because it is frequently
diffuse and bilateral. However, the adrenal tumors are rarely
malignant, are almost always intraadrenal, and usually secrete
epinephrine. His preference is that a patient with evidence for
disease in only one adrenal should undergo unilateral adrenalectomy initially. Thyroidectomy should be performed on individuals with abnormalities in calcitonin secretion at the earliest feasible time. Recently, the gene responsible for this disorder has been mapped to chromosome 10 at a point near the
centromere. It appears most likely that oncogenesis in this disorder is due to a deletion of a regulatory gene similar to that which
has been described in patients with retinoblastoma. In
MEN-2A, this deletional mutation is present near the centromere of chromosome 10. It is hoped that these studies will
lead soon to the ability to diagnose this disease at birth which
may lead to changes in the therapeutic approach (particularly
with respect to timing of thyroidectomy) and an improvement in
the overall prognosis. At the present time, in patients who are
screened and diagnosed as having underlying thyroid disease
before the onset of symptoms, about 90% are disease-free at five
years if they are subjected to total thyroidectomy.
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